

2:45

### 792-3 Differential Impact of Stent versus PTCA on Restenosis in Large ( $\geq 3$ mm) and Small ( $< 3$ mm) Vessels in the STent REStenosis Study

S. Chiu Wong, John Hirshfeld, Paul Teirstein, Richard Schatz, Alex Shaknovich, Masakiyo Nobuyoshi, Lowell F. Satler, Ya Chien Chuang, Martin B. Leon  
Washington Hospital Center, Washington, DC

To determine the impact of reference vessel size on restenosis (RES) in the multicenter randomized STent REStenosis Study (STRESS), we compared stent (S) vs PTCA in large ( $\geq 3$  mm by ImageComm quantitative angiographic edge detection methods) and small ( $< 3$  mm) vessels.

	S $\geq 3$ mm N = 102	PTCA $\geq 3$ mm N = 90	S $< 3$ mm N = 102	PTCA $< 3$ mm N = 111
Final % stenosis	20 $\pm$ 10	34 $\pm$ 11 <sup>†</sup>	17 $\pm$ 13	36 $\pm$ 17 <sup>†</sup>
Acute gain (mm)	1.86 $\pm$ 0.44	1.39 $\pm$ 0.52 <sup>†</sup>	1.58 $\pm$ 0.44	1.10 $\pm$ 0.40 <sup>†</sup>
Late loss (mm)	0.71 $\pm$ 0.58	0.38 $\pm$ 0.60**	0.78 $\pm$ 0.55	0.49 $\pm$ 0.53**
Net gain (mm)	1.11 $\pm$ 0.62	0.98 $\pm$ 0.65	0.85 $\pm$ 0.59	0.63 $\pm$ 0.53*
RES ( $\geq 50\%$ stenosis)	25.6	28.9	35.6	52.4*

\*P < 0.05, \*\*P < 0.001, <sup>†</sup>P < 0.0001 compared PTCA with S

For large and small vessels, S (compared to PTCA) had greater acute gain due to lower final % stenosis but S also had greater late loss. Nevertheless, net gain was still greater in S pts resulting in lower RES (vs PTCA). Late angiographic responses to S and PTCA were different in large and small vessels; S had similar late loss irrespective of vessel size, whereas PTCA had less late loss in  $\geq 3$  mm vessels which partially neutralizes the acute gain benefit of S. Thus, although RES was generally lower in  $\geq 3$  mm vessels, there was little difference among S and PTCA pts. In  $< 3$  mm vessel, absolute RES was higher and there was a marked difference in RES between S and PTCA. Importantly, late clinical events showed a similar differential response; target lesion revascularization (CABG or repeat PTCA) was similar for S and PTCA in  $\geq 3$  mm vessels (15 vs 13%, NS) but in  $< 3$  mm vessels was lower in S pts (22 vs 32%, P = 0.1). *In conclusion:* Data from STRESS indicate that S had a greater impact on lowering RES and increasing clinical benefit in smaller ( $< 3$  mm) vs larger ( $\geq 3$  mm) vessels. Future designs efforts should be directed towards developing a smaller S which can be safely implanted in smaller coronary vessels.

3:00

### 792-4 Three Years Clinical and Quantitative Angiographic Follow-up After the Palmaz-Schatz Coronary Stent Implantation

Takeshi Kimura, Hiroyoshi Yokoi, Takashi Tamura, Yoshihisa Nakagawa, Hideyuki Nosaka, Masakiyo Nobuyoshi. Kokura Memorial Hospital, Kitakyushu, Japan

Despite its proven efficacy in reducing restenosis in selected lesions, one of the greatest uncertainties of coronary stenting is longer-term results associated with permanent placement of metallic prosthetic devices. To evaluate efficacy and safety in long-term, a prospective serial angiographic study at 6 months (mos), 1 year (yr) and 3 yrs was designed. Between June 1990 to July 1991, single Palmaz-Schatz stent implantation for native coronary arteries was successful in 94 patients (pts) (age: 63  $\pm$  9, male 77%, multivessel disease: 49% or 97 lesions (les) (LAD: 51%, RCA: 34%, Cx: 7%, LMCA: 8%, restenotic lesion: 54%, bail-out use: 24%). At 3 yrs, 93% of pts were alive, 88% free from death/MI/CABG and 79% free from death/MI/CABG/target lesion revascularization (TLR). Six mos follow-up angiography (FUA) was performed and cine films were available in 88 pts (94%). Nine pts (9.6%) underwent TLR and 3 pts died (cardiac: 1, non-cardiac: 2) within 12 mos. Excluding these 12 pts, 82 pts (85 les) were eligible for longer-term FU. FUA at 1 and 3 yrs was performed in 73 pts (89%), and 49 pts (60%), respectively. CAAS II was used for quantitative analysis.

	Pre	Post	6 mos	1 yr	3 yrs
N of les	52	52	52	52	52
Interval (days)	-	-	193 $\pm$ 21	374 $\pm$ 24	1068 $\pm$ 105
MLD (mm)	1.00 $\pm$ 0.42	2.56 $\pm$ 0.5	1.98 $\pm$ 0.53	1.97 $\pm$ 0.52	2.12 $\pm$ 0.53
Ref (mm)	3.15 $\pm$ 0.58	3.42 $\pm$ 0.6	3.06 $\pm$ 0.6	3.07 $\pm$ 0.56	3.12 $\pm$ 0.56

MLD = minimal lumen diameter, Ref = Interpolated reference diameter

MLD improved between 6 mos and 3 yrs (P = 0.016) and did not change between 6 mos and 1 yr. Clinical events beyond 1 yr was analyzed in pts with or without FUA at 3 yrs. In 49 pts with FUA at 3 yrs, 2 pts (4%) suffered from MI unrelated to the stented les. TLR and PTCA for new les were required in 2 pts (4%) and 9 pts (18%) respectively. In 33 pts without FUA at 3 yrs, 3 pts (9%) died from definite non-cardiac causes and 2 pts (6%) underwent TLR due to angiographic restenosis at 1 yr FUA. *In conclusion,* safety and efficacy of stents appeared to be sustained at 3 yrs.

3:15

### 792-5 Three Year Follow-up After Intracoronary Stent Implantation

Bruce D. Klugherz, Back K. Kim, Debra L. DeAngelo, Howard C. Herrmann, John W. Hirshfeld, Jr., Daniel M. Kolansky. University of Pennsylvania, Philadelphia, PA

To identify predictors of long-term success following intracoronary stenting, we analyzed clinical outcome in 65 consecutive patients who electively received Palmaz-Schatz stents at least 3 years prior to analysis. 83 stents were successfully inserted in 63 of 65 patients (97%), of whom 49 (75%) were men and 16 (25%) were women, with a mean age ( $\pm$ SD) of 59  $\pm$  9 years. 18 patients (28%) were diabetic. 16 patients (24%) required more than one stent. Indications for stenting included restenosis following prior PTCA (52%) and lesion complexity (43%). 10 patients (15%) received stents in saphenous vein grafts.

Demographic, clinical, and procedural predictors of survival and event-free survival at a mean follow-up of 39  $\pm$  17 months were analyzed. Event-free survival was defined as survival without MI, CABG, PTCA at the stent site, or recurrent target vessel ischemia. Survival and event-free survival at 3 years were 86% and 54%, respectively. Predictors of decreased long term survival (p < 0.05) included diabetes, and a high angina score (Canadian Heart Class 3-4) at 6 and 12 months following stenting. Predictors of decreased event-free survival (p < 0.05) included smaller balloon size at implantation, greater number of stents at the primary lesion, and high angina score at each follow-up interval. Freedom from adverse events by 6 months following stenting correlated with long term success. 35 of 44 patients (80%) with event-free survival at 6 months remained event-free at follow-up. During follow-up, 17 patients (27%) developed symptomatic stent restenosis, requiring primarily early revascularization; 18 patients (28%) developed symptomatic stenoses in other vessels, requiring primarily late revascularization.

We conclude that: (1) long term survival after stenting is excellent; (2) the need for late revascularization is dictated primarily by disease progression in non-stented vessels; and (3) long-term success of stenting is predicted by freedom from adverse events at 6 months.

3:30

### 792-6 Late Lesion Regression within the Gianturco-Roubin Flex-Stent

James B. Hermiller, Edward T. Fry, Thomas F. Peters, Charles M. Orr, James Van Tassel, Belinda Ness, Cass A. Pinkerton. St. Vincent Hospital, Indianapolis, IN

The late angiographic outcome of the Gianturco-Roubin (GR) intracoronary stent is not well defined. To investigate serial changes within the stent, we studied 13 patients (9 men, 4 women; mean age 63) status-post GR stenting, who had acute, 6-month, and chronic (C) (>12 month) angiographic follow-up without intervening PTCA. Single stents were inserted in 11 patients and double stents in two. Average time to chronic follow-up was 21 months. Electronic calipers were used to determine pre, post, 6-mo, and chronic stent and coronary dimensions, which included MLD (minimum lumen diameter), % sten (% diameter stenosis), and REF (reference dimension). Data are expressed as mean  $\pm$  1 SD.

Results:

	MLD (mm)	% Sten	REF (mm)
Pre	0.95 $\pm$ 12	69 $\pm$ 6%	2.8 $\pm$ 0.17
Post	2.3 $\pm$ 0.16	20 $\pm$ 5%	2.9 $\pm$ 0.14
6 mo	1.6 $\pm$ 0.15	39 $\pm$ 6%	2.6 $\pm$ 0.13
C	2.1 $\pm$ 0.13*	23 $\pm$ 4%*	2.7 $\pm$ 0.15

\*P < 0.05 C vs. 6-mo

No patient had a significant decline in MLD or an increase in % stenosis at C vs. 6 months. Five had a greater than 50% increase in MLD at C.

*Conclusion:* Long term follow-up demonstrates late lesion regression, which is sometimes dramatic within the GR stent. These data have important clinical implications and suggest that coronary arteriography at 6-months may underestimate the chronic angiographic benefit of the intracoronary Gianturco-Roubin Flex-Stent.